However, within post hoc subphenotype analysis there was a benefit of simvastatin in patients exhibiting molecularly-defined hyperinflammatory ARDS, suggesting a potential role for increased CD73 activity impacting a spectrum of this syndrome (Calfee et al., 2018). This evidence concerns the gene NT5E and acute respiratory distress syndrome.